Taltz Autoinjector
Taltz Autoinjector Uses, Dosage, Side Effects, Food Interaction and all others data.
Taltz Autoinjector is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody (mAb) against interleukin-17A (IL-17A) and prevents it from interacting with the IL-17A receptor. As IL-17A is a pro-inflammatory cytokine involved in inflammation and immune responses, blocking its effect is beneficial for use in inflammatory conditions. In particular, IL-17A has been found to be implicated in a variety of autoimmune diseases including Rheumatoid Arthritis and plaque psoriasis.
Taltz Autoinjector is produced by recombinant DNA technology in a recombinant mammalian cell line and purified using standard technology for bioprocessing. Taltz Autoinjector is comprised of two identical light chain polypeptides of 219 amino acids each and two identical heavy chain polypeptides of 445 amino acids each, and has a molecular weight of 146,158 Daltons for the protein backbone of the molecule. It is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
| Trade Name | Taltz Autoinjector |
| Availability | Prescription only |
| Generic | Ixekizumab |
| Ixekizumab Other Names | Ixekizumab |
| Related Drugs | Taltz, Humira, Otezla, Cosentyx, Cimzia, prednisone, naproxen, methotrexate, Enbrel, Remicade |
| Weight | 80mg/ml, |
| Type | Subcutaneous solution |
| Formula | C6492H10012N1728O2028S46 |
| Weight | 146158.0 Da |
| Groups | Approved, Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | United States |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Taltz Autoinjector is a monoclonal antibody used to treat moderate to severe plaque psoriasis.
Taltz Autoinjector is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
Taltz Autoinjector is also used to associated treatment for these conditions: Severe Plaque psoriasis, Moderate Plaque psoriasis
How Taltz Autoinjector works
Taltz Autoinjector is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody (mAb) against interleukin-17A (IL-17A) and prevents it from interacting with the IL-17A receptor. As IL-17A is a pro-inflammatory cytokine involved in inflammation and immune responses, blocking its effect is beneficial for use in inflammatory conditions. In particular, IL-17A has been found to be implicated in a variety of autoimmune diseases including Rheumatoid Arthritis and plaque psoriasis.
Toxicity
The most common adverse reactions associated with Taltz Autoinjector treatment are injection site reactions, upper respiratory tract infections, nausea, and tinea infections.
Food Interaction
No interactions found.Taltz Autoinjector Drug Interaction
Unknown: aspirin, charcoal, celecoxib, sulfamethoxazole / trimethoprim, ubiquinone, copper gluconate, carvedilol, glucose, diltiazem, glycerin, heparin, sodium iodide, ferrous sulfate, empagliflozin, arginine, levocarnitine, cysteine, furosemide, acetaminophen, cholecalciferol
Taltz Autoinjector Disease Interaction
Moderate: infections, inflammatory bowel disease, tuberculosisMinor: renal/hepatic impairment
Volume of Distribution
The mean (geometric CV%) volume of distribution at steady-state was 7.11 L (29%) in subjects with plaque psoriasis.
Elimination Route
Following a single subcutaneous dose of 160 mg in subjects with plaque psoriasis, ixekizumab reached peak mean (±SD) serum concentrations (Cmax) of 16.2 ±6.6 mcg/mL by approximately 4 days post dose.
Half Life
13 days
Clearance
0.39 L/day
Innovators Monograph
You find simplified version here Taltz Autoinjector
